A novel design of one-side coated biodegradable intrascleral implant for the sustained release of triamcinolone acetonide

Biodegradable Intrascleral Implant of Triamcinolone Acetonide in Experimental Uveitis

“…23 The release profi les of the TA implant showed constant TA release over 90 days in vitro. In particular, the TA implants released 8% (539 μg of the 6.4 mg) of their initial TA loading over 90 days in vitro, indicating that TA release extends well beyond 90 days.…”

“…The intraocular pressures (IOPs) were not found to be significantly changed after the intrascleral implantation of this TA implant in an animal study. 23 The devised TA implant has one-side coating with non-TA containing high-molecular-weight PLA. The highmolecular-weight PLA coating was chosen to prevent drug absorption through conjunctival blood vessels and lymphatics, and thus, to minimize systemic absorptions and render unidirectional drug absorption through the sclera.…”

“…22 Previous reports have been issued on the in vitro and in vivo release profi les and on the safety of intrascleral TA implants comprised of poly(d,l-lactide) (PLA) and TA. 23 In this study, the effi cacy of an intrascleral TA implant was investigated for the treatment of experimental chronic uveitis in rabbit eyes.…”

“…23 Briefl y, 20 mg of PLA (MW: 125,000; Polyscience, Inc., Warrington, PA, USA) and 80 mg of crystalline powdered TA (Dongkwang Pharmacy, Co., Korea) were dissolved in 10 mL of dichloromethane, and then 2 mL of distilled water was added to produce an emulsion. The mixed solution was then frozen at −80°C and lyophilized for 24 h to obtain a homogeneous cake.…”

Evaluation of extended release brimonidine intravitreal device in normotensive rabbit eyes

“…Advances in the polymer technology has led to development of devices made up of bio-degradable polymers such as Poly-L-Lactic Acid (PLA) that can deliver a drug moiety intraocularly over a sustained period at a predetermined release rate (Robinson et al 2002;Cui et al 2008;Kim et al 2008;Bertram et al 2009). The purpose of this study was to evaluate the safety of a brimonidine impregnated sustained release intravitreal device in rabbit eyes over a period of 6 months by clinical examination, serial ERG and histopathology.…”